NGeneBio Amends Paid-in Capital Increase Details
엔젠바이오
354200
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=2585
Risk-adjusted indicator based on 2585 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEGATIVE
Key Numbers
- • Previous Operating Funds: 17,315,250,000 KRW
- • Amended Operating Funds: 3,679,100,000 KRW
- • Previous Debt Repayment Funds: 5,100,000,000 KRW
- • Amended Debt Repayment Funds: 4,000,000,000 KRW
- • Previous Issuance Price: 3,135 KRW/Share
- • Amended Issuance Price: 1,074 KRW/Share
- • Pre-reduction Shares: 26,809,750 Shares
- • New Share Allotment Ratio: 0.8008047920 Shares per existing share
- • Discount Rate: 25%
AI Analysis Summary
NGeneBio Co., Ltd. announced an amendment to its paid-in capital increase, significantly revising the allocation of funds and the new share issuance price. Operating funds were reduced from 17.31B KRW to 3.68B KRW, and debt repayment funds decreased from 5.1B KRW to 4.0B KRW. The issuance price for common shares was sharply cut from 3,135 KRW to 1,074 KRW, reflecting a 25% discount rate. This substantial reduction in issuance price and overall funding size, coupled with a pre-reduction share count of 26,809,750 shares and a new share allotment ratio of 0.8008 shares per existing share, indicates a significant dilution for existing shareholders. The amendment suggests challenges in securing funds at the initial valuation, potentially signaling weaker market confidence or a need to make the offering more attractive, which is a negative for current investors.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.